Featured Research

from universities, journals, and other organizations

Personalized vaccine for most lethal type of brain tumor shows promise

Date:
December 16, 2013
Source:
Northwestern Memorial Hospital
Summary:
Patients with recurrent glioblastoma multiforme treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine.

Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.

Related Articles


A GBM took the life of former Senator Edward Kennedy in 2009. The most aggressive form of primary brain tumor, GBM tumors are often resistant to standard therapies and median survival is approximately three to nine months for a recurrent tumor.

"We are talking about fast-growing tumors that invade normal brain tissue and are very difficult to treat," said Orin Bloch, MD, a neurosurgeon at Northwestern Memorial Hospital and lead author of the study. "These tumors occur in up to 23,000 Americans annually, and are typically treated with surgical resection of the tumor followed by chemotherapy and radiation treatment."

This phase 2 trial enrolled 41 adult patients with recurrent tumors between 2007 and 2011. Each patient received an average of six doses of the HSPPC-96 vaccine. Following treatment, 90 percent of patients were alive at six months and 30 percent were alive after one year. Further study will be needed to see if this vaccine could potentially be approved to treat recurrent brain tumors. Currently there are only a few approved therapeutic cancer vaccines, none of which are approved for the treatment of GBM.

While new findings continue to extend the lives of patients with glioblastoma, for the moment, it remains one of the most dreaded diagnoses because despite treatment, GBMs almost always come back, said Bloch.

"The grim prognosis is exactly why new research is important," said Bloch, who is an assistant professor of neurological surgery at the Northwestern Feinberg School of Medicine. "GBMs have been around for a long time, and still outcomes are poor. With studies such as this one, I believe we can change that."

The vaccine, HSPPC-96, is produced individually for each patient using that patient's own resected tumor tissue. Following the patient's surgery, the tumor is sent to the vaccine production facility at Agenus Inc., where the HSPPC-96 vaccine is created. The vaccine is unique to the individual participant and is engineered to trigger an immune system response to kill tumor cells that may remain following surgery.

Northwestern Medicineฎ researchers are currently conducting the next phase of this research, a randomized phase II trial which will investigate if the HSPPC-96 vaccine is safe and more effective when given with Avastin (bevacizumab). Avastin is a drug that is known to shrink brain tumors and is a standard therapy for recurrent GBM.

"When it comes to brain tumor research, I picture our Northwestern Medicine team climbing a mountain and with every new discovery that shows the potential to prolong survival, we are establishing a new base camp," said Andrew Parsa, MD, corresponding author of the study and chair of neurological surgery at Northwestern Memorial and the Michael J. Marchese Professor and chair of the department of neurological surgery at the Feinberg School. "Someday, thanks to studies like this one, we'll get to the top of the mountain and convert this particular cancer into a chronic disease -- something that patients can live with, controlled by medication."


Story Source:

The above story is based on materials provided by Northwestern Memorial Hospital. Note: Materials may be edited for content and length.


Journal Reference:

  1. O. Bloch, C. A. Crane, Y. Fuks, R. Kaur, M. K. Aghi, M. S. Berger, N. A. Butowski, S. M. Chang, J. L. Clarke, M. W. McDermott, M. D. Prados, A. E. Sloan, J. N. Bruce, A. T. Parsa. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro-Oncology, 2013; DOI: 10.1093/neuonc/not203

Cite This Page:

Northwestern Memorial Hospital. "Personalized vaccine for most lethal type of brain tumor shows promise." ScienceDaily. ScienceDaily, 16 December 2013. <www.sciencedaily.com/releases/2013/12/131216080500.htm>.
Northwestern Memorial Hospital. (2013, December 16). Personalized vaccine for most lethal type of brain tumor shows promise. ScienceDaily. Retrieved October 24, 2014 from www.sciencedaily.com/releases/2013/12/131216080500.htm
Northwestern Memorial Hospital. "Personalized vaccine for most lethal type of brain tumor shows promise." ScienceDaily. www.sciencedaily.com/releases/2013/12/131216080500.htm (accessed October 24, 2014).

Share This



More Health & Medicine News

Friday, October 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) — An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins